Metafora Biosystems news
3rd February 2022 - SFNP Congress
We are delighted to have been able to participate in the 31st congress of the SOCIETE FRANCAISE DE NEUROLOGIE PEDIATRIQUE (SFNP) to present the results of the validation study of our METAglut1 test aimed at improving the early diagnosis of De Vivo’s disease.
Sebia, a world leader in diagnostics in the fields of multiple myeloma and chronic diseases, and Metafora biosystems ("Metafora") today announced a strategic partnership to develop a portfolio of in-vitro diagnostics (IVD) solutions based on Metafora`s technology platform. Metafora leverages a single-cell Al-powered diagnostic platform for the detection of cellular metabolism anomalies. In conjunction with the agreement, Sphinx, Sebia`s parent company, has acquired a minority share in Metafor
Laboratoire Cerba and METAFORA biosystems are proud to announce the availability of the innovative test METAglut1 in routine biology to help diagnose the GLUT1 deficiency syndrome (GLUT1-DS) Laboratoire Cerba will perform the METAglut1 diagnostics test developed by METAFORA for the early non-invasive diagnosis of a debilitating neurological disease, the GLUT1 deficiency syndrome (also named De Vivo disease). This disease which affects mostly children is due to a lack of expression of
The technological platform developed by METAFORA enables the evaluation of cells’ energy needs in connection with patients’ health. “The investigation into altered metabolic functions for the preve
Vincent Petit, CEO of METAFORA Biosystems, presented the strategic plans of the company at the First International meeting of Biotechnology organized by the French organization for promotion of innovation BPI France and the French Pharmaceutical association companies, LEEM, July 1st 2015 in Paris. The project was selected with 16 other French biotechs to meet a delegation of International Big Pharmas to promote ambitious partnerships.